TY - JOUR
T1 - High-Dose Chemotherapy for Adult-Type Ovarian Granulosa Cell Tumors
T2 - A Retrospective Study of the European Society for Blood and Marrow Transplantation
AU - De Giorgi, Ugo
AU - Nicolas-Virelizier, Emmanuelle
AU - Badoglio, Manuela
AU - Bader, Peter
AU - Richard, Sandrine
AU - Maertens, Johan
AU - Lanza, Francesco
AU - Bregni, Marco
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Objectives A few small retrospective series reported results with salvage chemotherapy for malignant ovarian adult-type granulosa cell tumors (GCTs), whereas no data are available on high-dose chemotherapy (HDC) with hematopoietic progenitor cell support (HSCS) in these patients. The aim of this study was to analyze the available data of HDC for adult-type GCTs. Methods We conducted a retrospective analysis of ovarian cancer treated with salvage HDC registered with the European Society for Blood and Marrow Transplantation. Results Of 203 adult female patients with a diagnosis of nonepithelial ovarian cancer treated with salvage HDC with HSCS and registered with the European Society for Blood and Marrow Transplantation, 4 (2%) patients were affected by GCTs. All 4 patients had ovarian adult-type GCTs that relapsed/progressed after first-line chemotherapy. The conditioning regimens included a platinum agent in all 4 patients. Bone marrow recovery was promptly achieved; neither treatment-related deaths or life-threatening toxicities occurred. At a median follow-up of 8.5 months, all patients reported a progressive disease. The patient who underwent multicycle HDC enjoyed a long-term remission of 84 months before progression and is the only one alive after 94+ months. Conclusions We showed for the first time a case with long-lasting response to salvage multicycle HDC and HSCS in adult-type GCTs.
AB - Objectives A few small retrospective series reported results with salvage chemotherapy for malignant ovarian adult-type granulosa cell tumors (GCTs), whereas no data are available on high-dose chemotherapy (HDC) with hematopoietic progenitor cell support (HSCS) in these patients. The aim of this study was to analyze the available data of HDC for adult-type GCTs. Methods We conducted a retrospective analysis of ovarian cancer treated with salvage HDC registered with the European Society for Blood and Marrow Transplantation. Results Of 203 adult female patients with a diagnosis of nonepithelial ovarian cancer treated with salvage HDC with HSCS and registered with the European Society for Blood and Marrow Transplantation, 4 (2%) patients were affected by GCTs. All 4 patients had ovarian adult-type GCTs that relapsed/progressed after first-line chemotherapy. The conditioning regimens included a platinum agent in all 4 patients. Bone marrow recovery was promptly achieved; neither treatment-related deaths or life-threatening toxicities occurred. At a median follow-up of 8.5 months, all patients reported a progressive disease. The patient who underwent multicycle HDC enjoyed a long-term remission of 84 months before progression and is the only one alive after 94+ months. Conclusions We showed for the first time a case with long-lasting response to salvage multicycle HDC and HSCS in adult-type GCTs.
KW - Adult-type ovarian granulosa cell tumors
KW - High-dose chemotherapy
KW - Ovarian cancer
KW - Salvage chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=85011711399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011711399&partnerID=8YFLogxK
U2 - 10.1097/IGC.0000000000000882
DO - 10.1097/IGC.0000000000000882
M3 - Article
C2 - 28114232
AN - SCOPUS:85011711399
VL - 27
SP - 248
EP - 251
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
SN - 1048-891X
IS - 2
ER -